(Q37504134)

20 August 2017

B-lymphocyte depletion with rituximab and β-cell function: two-year results (English)

1 reference

20 August 2017

0 references

1 reference

0 references

6

Robin Goland

1 reference

20 August 2017

15

Jeffrey P Krischer

1 reference

20 August 2017

2

Carla J Greenbaum

1 reference

20 August 2017

14

Darrell M Wilson

1 reference

20 August 2017

16

Jay S Skyler

1 reference

20 August 2017

4

Dorothy J Becker

1 reference

20 August 2017

Mark D Pescovitz

1

1 reference

20 August 2017

Brian Bundy

3

1 reference

20 August 2017

Stephen E Gitelman

5

1 reference

20 August 2017

Peter A Gottlieb

7

1 reference

20 August 2017

Jennifer B Marks

8

1 reference

20 August 2017

Antoinette Moran

9

1 reference

20 August 2017

Philip Raskin

10

1 reference

20 August 2017

Henry Rodriguez

11

1 reference

20 August 2017

Desmond A Schatz

12

1 reference

20 August 2017

Diane K Wherrett

13

1 reference

20 August 2017

Type 1 Diabetes TrialNet Anti-CD20 Study Group

17

1 reference

20 August 2017

language of work or name

English

0 references

publication date

11 September 2013

1 reference

20 August 2017

1 reference

20 August 2017

37

1 reference

20 August 2017

2

1 reference

20 August 2017

453-459

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

20 August 2017

start time

28 August 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Effect of rituximab on human in vivo antibody immune responses

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Molecules involved in T-B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

B cell-directed therapies in type 1 diabetes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3898764

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24026563

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24026563

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2337/DC13-0626

1 reference

20 August 2017

1 reference

20 August 2017

1 reference